Edition:
India

Calithera Biosciences Inc (CALA.OQ)

CALA.OQ on NASDAQ Stock Exchange Global Select Market

4.10USD
16 Sep 2019
Change (% chg)

-- (--)
Prev Close
$4.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
95,299
52-wk High
$6.90
52-wk Low
$3.43

Latest Key Developments (Source: Significant Developments)

Calithera Biosciences Says Q2 Loss Per Share $0.58
Friday, 9 Aug 2019 

Aug 8 (Reuters) - Calithera Biosciences Inc ::CALITHERA BIOSCIENCES REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q2 LOSS PER SHARE $0.58.Q2 EARNINGS PER SHARE ESTIMATE $-0.56 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $153.2 MILLION AT JUNE 30, 2019.  Full Article

Calithera Biosciences Initiates Phase 1/2 Trial Of Telaglenastat
Tuesday, 2 Jul 2019 

July 2 (Reuters) - Calithera Biosciences Inc ::CALITHERA BIOSCIENCES INITIATES PHASE 1/2 TRIAL OF TELAGLENASTAT IN COMBINATION WITH PFIZER’S CDK4/6 INHIBITOR PALBOCICLIB.CALITHERA BIOSCIENCES - ANNOUNCED TREATMENT OF FIRST PATIENT IN PHASE 1/2 TRIAL OF GLUTAMINASE INHIBITOR TELAGLENASTAT WITH PFIZER'S IBRANCE.CALITHERA BIOSCIENCES INC - AS PART OF AGREEMENT, PFIZER IS PROVIDING PALBOCICLIB AND TALAZOPARIB, AS WELL AS FINANCIAL SUPPORT.  Full Article

Calithera Biosciences, Inc. Prices Public Offering Of 12,500,000 Shares Of Common Stock
Wednesday, 19 Jun 2019 

June 18 (Reuters) - Calithera Biosciences Inc ::CALITHERA BIOSCIENCES, INC. PRICES PUBLIC OFFERING OF 12,500,000 SHARES OF COMMON STOCK.SAYS PUBLIC OFFERING OF 12.5 MILLION COMMON SHARES PRICED AT $4.00PER SHARE.GROSS PROCEEDS TO CALITHERA FROM OFFERING ARE EXPECTED TO BE $50 MILLION.  Full Article

Calithera Biosciences Reports Fourth Quarter 2018 Financial Results And Recent Highlights
Friday, 8 Mar 2019 

March 7 (Reuters) - Calithera Biosciences Inc ::CALITHERA BIOSCIENCES REPORTS FOURTH QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.QTRLY LOSS PER SHARE $0.51.Q4 EARNINGS PER SHARE VIEW $-0.49 -- REFINITIV IBES DATA.  Full Article

Calithera Biosciences Q3 Operating Loss Per Share $0.52
Thursday, 8 Nov 2018 

Nov 7 (Reuters) - Calithera Biosciences Inc ::CALITHERA BIOSCIENCES REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q3 OPERATING LOSS PER SHARE $0.52.Q3 EARNINGS PER SHARE VIEW $-0.40 -- THOMSON REUTERS I/B/E/S.AS OF SEPTEMBER 30, 2018, CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $141.5 MILLION.EXPECT DATA ON INCB001158 TO BE PRESENTED AT A MEDICAL MEETING IN FIRST HALF OF 2019.  Full Article

Calithera Biosciences Qtrly Net Loss From Operations $11.0 Mln
Friday, 9 Mar 2018 

March 8 (Reuters) - Calithera Biosciences Inc ::CALITHERA BIOSCIENCES REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.CALITHERA BIOSCIENCES INC QTRLY NET LOSS FROM OPERATIONS $11.0 MILLION.CALITHERA BIOSCIENCES - EXPECTS CASH, CASH EQUIVALENTS AND INVESTMENTS WILL BE BETWEEN $105 AND $115 MILLION AT END OF 2018.CALITHERA - EXPECTS CASH, CASH EQUIVALENTS & INVESTMENTS WILL BE SUFFICIENT TO MEET CURRENT OPERATING PLAN THROUGH 2020, EXCLUSIVE OF SOME ITEMS.  Full Article

Calithera Biosciences expands clinical collaboration with Bristol-Myers Squibb
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Calithera Biosciences Inc :Initial results from Phase 2 study of CB-839 in combination with opdivo® (nivolumab) to be presented at the Society for Immunotherapy of Cancer Meeting.Calithera Biosciences Inc - ‍expanding Bristol-Myers Squibb clinical collaboration​.Calithera Biosciences Inc - ‍expanded its existing clinical collaboration with Bristol-Myers Squibb, evaluating CB-839 in combination with opdivo​.Calithera Biosciences Inc - ‍analysis of all safety evaluable patients demonstrated CB-839 was well tolerated when combined with opdivo​.Calithera Biosciences - ‍among 16 evaluable melanoma patients, one patient achieved a complete response and two patients achieved partial responses​.Calithera Biosciences Inc - ‍study will be expanded to enroll additional melanoma patients​.Calithera Biosciences Inc - ‍as part of expanded collaboration, melanoma development costs will be shared​.  Full Article

Calithera Biosciences Q3 operating loss per share $0.17
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Calithera Biosciences Inc :Calithera biosciences reports third quarter 2017 financial results and recent highlights.Q3 operating loss per share $0.17.Q3 revenue $7.3 million.Q3 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.Q3 revenue view $4.5 million -- Thomson Reuters I/B/E/S.Calithera biosciences inc - ‍as of september 30, 2017, cash, cash equivalents and investments totaled $196.5 million​.Calithera biosciences inc - qtrly ‍research and development expenses were $10.8 million compared with $6.3 million for same period in prior year​.  Full Article